Enfermedad por hígado graso no alcohólico en pediatría
Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of liver disease in children and adolescents in the United States of America (USA) and probably in the entire western hemisphere, due to the increase in the prevalence of overweight and obesity. Steatosis can progress to inf...
| Autor: | |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2014 |
| País: | México |
| Recursos: | Instituto Mexicano del Seguro Social |
| Repositorio: | Redalyc-IMSS |
| OAI Identifier: | oai:redalyc.org:457745485018 |
| Acesso em linha: | https://www.redalyc.org/articulo.oa?id=457745485018 |
| Access Level: | acceso abierto |
| Palavra-chave: | Medicina Fatty liver |
| Resumo: | Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of liver disease in children and adolescents in the United States of America (USA) and probably in the entire western hemisphere, due to the increase in the prevalence of overweight and obesity. Steatosis can progress to infl ammation, fi brosis and even cirrhosis, which increases the morbidity and mortality associated to liver disease. In every over-weight and obese child a thorough analysis should be performed includ-ing liver function tests and liver ultrasound, in order to establish a timely diagnosis. The liver biopsy is the most specifi c study to rule out other potentially treatable entities. It is necessary to count on non-invasive methods to detect children with NAFLD and identify those in risk of pro-gression. Biomarkers related to infl ammation, oxidative stress, apoptosis and fi brosis have been reported. The main goal of the treatment is to modify the life style, starting with a healthy diet and an increase of physi-cal activity. Regarding pharmacological treatment, there is evidence of histological improvement with vitamin E use, as opposed to metformin, but more conclusive studies regarding this subject are needed. |
|---|